



## WORKING GROUP MEETING MINUTES: Cost Effectiveness Working Group

7<sup>th</sup> October 2021

Meeting details	
Meeting location	MS Teams online
Meeting date	Thursday 7 <sup>th</sup> October 2021
Meeting time	13.00-14.00 CET
Chair(s)	Job Van Boven
Attendees	Job Van Boven Wenjia Chen Graham Lough Ted Popov
Objectives	
1	Update on potential projects

Items	
Update on potential projects	<ol style="list-style-type: none"><li><b><u>Do clinical guidelines consider / incorporate cost effectiveness in their treatment recommendations?</u></b><ul style="list-style-type: none"><li>The group discussed the previously suggested scoping review highlighting gaps in clinical guidelines where cost of treatment is not considered.</li><li>A research proposal has been drafted adding a priority-setting task for guideline developers.</li><li>It was agreed that this project should be put on hold until early 2022 to increase chance of funding.</li></ul></li><li><b><u>REG/Novartis Breezhaler project.</u></b><ul style="list-style-type: none"><li>The group discussed implementing an add-on cost effectiveness study to the Novartis-funded project developed project in the REG Technologies working group.</li><li>Two potential models were outlined which could be adapted for adherence to the Breezhaler in uncontrolled asthma patients from either Zafar Zafari or Job.</li><li>The implementation of the model across multiple countries was discussed e.g. GDP/WHO thresholds.</li></ul></li></ol>
Action Points	<ul style="list-style-type: none"><li>Graham to send Breezhaler project research proposal to the group for comments on how best to perform CE analysis.</li><li>Graham to contact Novartis to see about attaching this project.</li></ul>